EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Gut microbiota impact on lung diseases: a mini review of clinical evidence

Chuanfeng Liu iD, Lingying Dan, Xuebin Wang, Lingyong Chen, Xingxing Yuan iD

Infection and Immunity · 2026

DOI: 10.1128/iai.00430-25 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Infection and Immunity, 2026. Verfasst von Chuanfeng Liu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pulmonary and Critical Care Medicine, Lishui Hospital of Traditional Chinese Medicine, Lishui, China. Hauptthemen laut MEDLINE: Gastrointestinal Microbiome, Lung Diseases. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 84 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Youth Talent Cultivation Program of the China Association of Chinese Medicine, Science and Technology Project of Lishui.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The gut-lung axis represents a bidirectional communication network through which the gut microbiota (GM) influences respiratory health. This mini-review synthesizes clinical evidence on the role of the GM in lung diseases. We focused exclusively on human clinical trials, randomized controlled trials, meta-analyses, and systematic reviews, sourced from major databases after duplicate removal. The evidence indicates that GM dysbiosis is a significant risk factor for the susceptibility and severity of various respiratory conditions, including asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and infections, such as COVID-19 and pneumonia. Specific microbial signatures and metabolic profiles, particularly involving short-chain fatty acids (SCFAs), are associated with disease states and outcomes. Interventions like probiotics, prebiotics, synbiotics, and fecal microbiota transplantation (FMT) show promise in modulating the GM and improving clinical parameters, though their efficacy can be inconsistent and influenced by confounding factors. In conclusion, the GM is a promising therapeutic target for lung diseases. However, future research must prioritize large-scale, longitudinal clinical trials and deeper mechanistic investigations to establish causality and develop effective, personalized microbiome-based therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Gastrointestinal MicrobiomeLung DiseasesHumansDysbiosisFecal Microbiota TransplantationProbioticsCOVID-19PrebioticsSARS-CoV-2

Stichwörter der Autor:innen

clinical significancedysbiosisgut microbiotagut-lung axismetabolites

Substanzen

Prebiotics

Autor:innen und Institutionen

  • Department of Pulmonary and Critical Care Medicine, Lishui Hospital of Traditional Chinese Medicine, Lishui, China.
  • Department of Endocrinology, Lishui Hospital of Traditional Chinese Medicine, Lishui, China.
  • First Clinical Medical College, Heilongjiang University of Chinese Medicine, Harbin, China.

ORCID-Profile: Chuanfeng Liu, Xingxing Yuan

Förderung

  • Youth Talent Cultivation Program of the China Association of Chinese Medicine
  • Science and Technology Project of Lishui

Zitieren

APA

Liu, C., Dan, L., Wang, X., Chen, L., & Yuan, X. (2026). Gut microbiota impact on lung diseases: a mini review of clinical evidence. Infection and Immunity. https://doi.org/10.1128/iai.00430-25

Vancouver

Liu C, Dan L, Wang X, Chen L, Yuan X. Gut microbiota impact on lung diseases: a mini review of clinical evidence. Infection and Immunity. 2026. doi:10.1128/iai.00430-25

BibTeX
@article{Liu2026,
  author = {Liu, Chuanfeng and Dan, Lingying and Wang, Xuebin and Chen, Lingyong and Yuan, Xingxing},
  title = {Gut microbiota impact on lung diseases: a mini review of clinical evidence},
  journal = {Infection and Immunity},
  year = {2026},
  doi = {10.1128/iai.00430-25}
}
Kostenlos starten →